Wai Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wai Chen has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Bronwyn Myers
Curtin enAble Institute, Faculty of Health Sciences, Curtin University
7 shared publications - Aimee-Rose Wrightson-Hester
Curtin enAble Institute, School of Population Health Faculty of Health Sciences Curtin University Perth, Western Australia Australia
6 shared publications - Chris Sutton
Lancashire Clinical Trials Unit, Allied Health Research Hub, University of Central Lancashire , Preston
6 shared publications - Joel Dunstan
Curtin Institute for Data Science Curtin University Perth, Western Australia Australia
6 shared publications - Melanie Johnston-Hollitt
Curtin Institute for Data Science Curtin University Bentley WA Australia
6 shared publications - Peter M. McEvoy
Discipline of Psychology, School of Population Health Curtin University Perth Western Australia Australia
6 shared publications
Latest Publications
- 10 August 2026
- Published by Wiley in Journal of Child Psychology and Psychiatry
The effect of atomoxetine and methylphenidate on emotional dysregulation in children with attention deficit/hyperactivity disorder: a multicenter randomized clinical trial
Background: This study aimed to compare the effects of atomoxetine (ATX) and methylphenidate (MPH) on emotional dysregulation (ED) in children with attention deficit/hyperactivity disorder (ADHD), and to explore potential neural correlates underlying treatment‐related changes. Methods: A total of 152 children with ADHD were randomly assigned to receive ATX ( n = 76) or MPH ( n = 76). After individualized dose titration, participants received a stable dose for 4 weeks. Emotional lability (EL) was the primary outcome, while emotion regulation strategies, ADHD symptoms, and overall illness severity were secondary outcomes. Mixed‐effects linear models were applied to examine group differences across three time points (baseline, post‐titration, and endpoint). Resting‐state functional MRI data were acquired at baseline and endpoint and analyzed using whole‐brain functional connectivity (FC) analysis with six amygdala subregions as seeds. Trial registration: ChiCTR2200062905; approved on August 23, 2022. Results: In both ATX and MPH groups, EL scores decreased significantly over time (β = −1.54, p < .001), with treatment effects in a similar range and no statistically significant between‐group difference (MPH: d = −1.46; ATX: d = −0.93). After controlling for ADHD symptom improvement, treatment effects remained significant (β = −0.75, p < .001), suggesting that EL improvement was not solely accounted for by ADHD symptom reduction. Increased FC between the right basolateral amygdala and left orbital middle frontal gyrus ( r = −0.46, p = .043), and between the left superficial amygdala and left middle cingulate cortex ( r = −0.48, p = .031), was associated with EL changes and remained significant after controlling for ADHD symptom changes. No significant changes were found in self‐reported emotion regulation strategies. Conclusions: ATX and MPH both alleviate ED in children with ADHD, and these effects are not solely accounted for by improvements in ADHD symptoms. Increased amygdala‐centered FC may be associated with medication‐related ED improvements.
- 10 August 2026
- Published by Wiley in Journal of Child Psychology and Psychiatry
The effect of atomoxetine and methylphenidate on emotional dysregulation in children with attention deficit/hyperactivity disorder: a multicenter randomized clinical trial
Background: This study aimed to compare the effects of atomoxetine (ATX) and methylphenidate (MPH) on emotional dysregulation (ED) in children with attention deficit/hyperactivity disorder (ADHD), and to explore potential neural correlates underlying treatment‐related changes. Methods: A total of 152 children with ADHD were randomly assigned to receive ATX ( n = 76) or MPH ( n = 76). After individualized dose titration, participants received a stable dose for 4 weeks. Emotional lability (EL) was the primary outcome, while emotion regulation strategies, ADHD symptoms, and overall illness severity were secondary outcomes. Mixed‐effects linear models were applied to examine group differences across three time points (baseline, post‐titration, and endpoint). Resting‐state functional MRI data were acquired at baseline and endpoint and analyzed using whole‐brain functional connectivity (FC) analysis with six amygdala subregions as seeds. Trial registration: ChiCTR2200062905; approved on August 23, 2022. Results: In both ATX and MPH groups, EL scores decreased significantly over time (β = −1.54, p < .001), with treatment effects in a similar range and no statistically significant between‐group difference (MPH: d = −1.46; ATX: d = −0.93). After controlling for ADHD symptom improvement, treatment effects remained significant (β = −0.75, p < .001), suggesting that EL improvement was not solely accounted for by ADHD symptom reduction. Increased FC between the right basolateral amygdala and left orbital middle frontal gyrus ( r = −0.46, p = .043), and between the left superficial amygdala and left middle cingulate cortex ( r = −0.48, p = .031), was associated with EL changes and remained significant after controlling for ADHD symptom changes. No significant changes were found in self‐reported emotion regulation strategies. Conclusions: ATX and MPH both alleviate ED in children with ADHD, and these effects are not solely accounted for by improvements in ADHD symptoms. Increased amygdala‐centered FC may be associated with medication‐related ED improvements.
- Open Access
- 25 February 2026
- Published by SAGE Publications in Clinical Child Psychology and Psychiatry
- Vol. 31 (4) , 1759-1774
Comorbidities Among Mental Disorders in Preschool Children in the Mercy Pregnancy Emotional Wellbeing Study
Background: Comorbidities among mental disorders can have long-term impacts on children’s development and mental health. There is little robust data about the prevalence of comorbidities in preschool-aged children. The aim was to identify the prevalence of comorbidities among mental disorders in a cohort of 3–4-year-old children in Australia. Methods: Women were recruited to the Australian Mercy Pregnancy Emotional Wellbeing Study at n = 545) met criteria for mental disorders captured by the PAPA; 43% had anxiety disorders. Of children with at least one diagnosis, 44% had another mental disorder; this represents 21% of the whole sample. Depressive disorders occurred only alongside other disorders, both anxiety disorders and externalising disorders. At least one anxiety disorder was present in more than half of children with specific externalising disorders. Conclusions: Comorbidity of mental disorders among preschool-aged children is relatively common. Preschool children presenting with mental health symptoms may benefit from assessment protocols which consider multiple mental health disorders, and integrated services to address these.
- 25 February 2026
- Published by SAGE Publications in Clinical Child Psychology and Psychiatry
- Vol. 31 (4) , 1759-1774
Open AccessComorbidities Among Mental Disorders in Preschool Children in the Mercy Pregnancy Emotional Wellbeing Study
Background: Comorbidities among mental disorders can have long-term impacts on children’s development and mental health. There is little robust data about the prevalence of comorbidities in preschool-aged children. The aim was to identify the prevalence of comorbidities among mental disorders in a cohort of 3–4-year-old children in Australia. Methods: Women were recruited to the Australian Mercy Pregnancy Emotional Wellbeing Study at n = 545) met criteria for mental disorders captured by the PAPA; 43% had anxiety disorders. Of children with at least one diagnosis, 44% had another mental disorder; this represents 21% of the whole sample. Depressive disorders occurred only alongside other disorders, both anxiety disorders and externalising disorders. At least one anxiety disorder was present in more than half of children with specific externalising disorders. Conclusions: Comorbidity of mental disorders among preschool-aged children is relatively common. Preschool children presenting with mental health symptoms may benefit from assessment protocols which consider multiple mental health disorders, and integrated services to address these.
- Open Access
- 1 December 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e69841
A Rule-Based Conversational Agent for Mental Health and Wellbeing in Young People: A Formative Case Series During the Rise of Generative AI
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: There is a shortage of services available to address the growing demand for mental health support in Australia and worldwide. Digital interventions, including conversational agents, can overcome barriers to accessing mental health support. The recent advances in large language models (LLMs) have led to an improvement in the perceived human-like naturalness of chatbot conversations, but there is little research on the experience of chatbots to support mental health. Manage Your Life Online (MYLO) is a rule-based chatbot that was co-designed with young people and uses questions to help users explore their problems. In a case series conducted prior to the release of ChatGPT, users rated a new smartphone interface for MYLO as acceptable and there was a large effect size for reduction in problem-related distress. Objective: We aimed to evaluate an improved version of MYLO and compare the user experience of MYLO in this case-series to the previous version that was completed in November 2022. Methods: We replicated and extended the previous two-week case-series, conducted in September to November 2022, by testing four-week usage of MYLO with a larger sample between October and December 2023. We recruited 24 young people living in Western Australia who self-described as having lived experience of anxiety and/or depression. Participants had access to, and used, MYLO over a four-week period while completing online weekly surveys that included a range of health and psychological questionnaires. After the four-week testing phase, participants were invited to provide feedback on their experience of using MYLO through an interview or focus group discussion. Results: Thirteen of the initial 24 participants were retained throughout the study and took part in interviews. On average, participants had around four conversations with MYLO. They experienced both benefits and limitations of these conversations. They spoke about their recent experiences with ChatGPT (released in November 2022 after the previous case-series concluded) and other generative AI tools, stating that they had expected MYLO to possess similar functionality, which it did not. Nonetheless, we found moderate to large effect sizes for improvements in problem-related distress (d = -1.07), anxiety (d = -0.41) and psychiatric impairment (d = 0.60) and some evidence of reliable improvement in clinical outcomes. Conclusions: These findings have implications for mental health chatbots in the age of ChatGPT and highlight a need for researchers to engage with new technologies to improve user experience, while maintaining the necessary safety and ethical standards that can be a significant challenged for generative AI.
- 1 December 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e69841
Open AccessA Rule-Based Conversational Agent for Mental Health and Wellbeing in Young People: A Formative Case Series During the Rise of Generative AI
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: There is a shortage of services available to address the growing demand for mental health support in Australia and worldwide. Digital interventions, including conversational agents, can overcome barriers to accessing mental health support. The recent advances in large language models (LLMs) have led to an improvement in the perceived human-like naturalness of chatbot conversations, but there is little research on the experience of chatbots to support mental health. Manage Your Life Online (MYLO) is a rule-based chatbot that was co-designed with young people and uses questions to help users explore their problems. In a case series conducted prior to the release of ChatGPT, users rated a new smartphone interface for MYLO as acceptable and there was a large effect size for reduction in problem-related distress. Objective: We aimed to evaluate an improved version of MYLO and compare the user experience of MYLO in this case-series to the previous version that was completed in November 2022. Methods: We replicated and extended the previous two-week case-series, conducted in September to November 2022, by testing four-week usage of MYLO with a larger sample between October and December 2023. We recruited 24 young people living in Western Australia who self-described as having lived experience of anxiety and/or depression. Participants had access to, and used, MYLO over a four-week period while completing online weekly surveys that included a range of health and psychological questionnaires. After the four-week testing phase, participants were invited to provide feedback on their experience of using MYLO through an interview or focus group discussion. Results: Thirteen of the initial 24 participants were retained throughout the study and took part in interviews. On average, participants had around four conversations with MYLO. They experienced both benefits and limitations of these conversations. They spoke about their recent experiences with ChatGPT (released in November 2022 after the previous case-series concluded) and other generative AI tools, stating that they had expected MYLO to possess similar functionality, which it did not. Nonetheless, we found moderate to large effect sizes for improvements in problem-related distress (d = -1.07), anxiety (d = -0.41) and psychiatric impairment (d = 0.60) and some evidence of reliable improvement in clinical outcomes. Conclusions: These findings have implications for mental health chatbots in the age of ChatGPT and highlight a need for researchers to engage with new technologies to improve user experience, while maintaining the necessary safety and ethical standards that can be a significant challenged for generative AI.
- Open Access
- 5 November 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (2) , 419-424
Guanfacine as a Treatment Option for Persistent Mental Restlessness and Deliberate Self-harm Thoughts in a Patient with Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Borderline Personality Disorder, and Post-traumatic Stress Disorder: Case Report
Jun-Ting Yeung, Phoebe Wan, Wai Chen. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.25.1352
- 5 November 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (2) , 419-424
Open AccessGuanfacine as a Treatment Option for Persistent Mental Restlessness and Deliberate Self-harm Thoughts in a Patient with Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Borderline Personality Disorder, and Post-traumatic Stress Disorder: Case Report
Jun-Ting Yeung, Phoebe Wan, Wai Chen. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.25.1352
- Open Access
- 28 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 576-586
Prevalence of attention deficit hyperactivity disorder/hyperkinetic disorder of pediatric and adult populations in clinical settings: a systematic review, meta-analysis and meta-regression
Background: Attention-Deficit/Hyperactivity Disorder (ADHD)/Hyperkinetic Disorder (HD) is linked to increased risks of morbidity, comorbidity and mortality, with higher prevalence in clinical populations. The differential prevalence of ADHD/HD across adult and pediatric clinical populations, influenced by factors such as time trends, sex, age, geographic regions, and comorbidities, has not been systematically assessed. Methods: MEDLINE, CINAHL, Embase and PsycINFO databases were searched from inception to 1st August 2023 for eligible full-text papers published in English, and reviewing reference lists of identified studies and review papers. Studies reporting ADHD/HD prevalence in adult and pediatric clinical populations were included. Meta-regression evaluated the effects of geographic region, year of publication and sample size. Results: From 30,740 citations, we reviewed 521 full-text articles, yielding 311 studies for inclusion (including 653,558 pediatric and 43,311 adult participants). Overall, worldwide pooled prevalence of ADHD/HD in clinical settings for pediatrics was 32.4% (95% CI 31–34%), and in adults 21.4% (95% CI 20–23%). Prevalence was higher in outpatient settings than inpatient settings. Prevalence based on rating scales was higher than studies using diagnostic interviews or clinical record review. Prevalence varied significantly across subspecialist settings for children and adults. No significant time trend was detected between 1981–2023. Pediatric prevalence appears influenced by geographic region but not year of publication or sample size. For adults, larger sample sizes were associated with lower prevalence estimates. Conclusions: ADHD/HD prevalence in clinical populations is 8-9-fold higher than community estimates. With these patients at risk for many adverse outcomes, our findings underscore the critical importance of resource allocation for screening, diagnosing and treatment.
- 28 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 576-586
Open AccessPrevalence of attention deficit hyperactivity disorder/hyperkinetic disorder of pediatric and adult populations in clinical settings: a systematic review, meta-analysis and meta-regression
Background: Attention-Deficit/Hyperactivity Disorder (ADHD)/Hyperkinetic Disorder (HD) is linked to increased risks of morbidity, comorbidity and mortality, with higher prevalence in clinical populations. The differential prevalence of ADHD/HD across adult and pediatric clinical populations, influenced by factors such as time trends, sex, age, geographic regions, and comorbidities, has not been systematically assessed. Methods: MEDLINE, CINAHL, Embase and PsycINFO databases were searched from inception to 1st August 2023 for eligible full-text papers published in English, and reviewing reference lists of identified studies and review papers. Studies reporting ADHD/HD prevalence in adult and pediatric clinical populations were included. Meta-regression evaluated the effects of geographic region, year of publication and sample size. Results: From 30,740 citations, we reviewed 521 full-text articles, yielding 311 studies for inclusion (including 653,558 pediatric and 43,311 adult participants). Overall, worldwide pooled prevalence of ADHD/HD in clinical settings for pediatrics was 32.4% (95% CI 31–34%), and in adults 21.4% (95% CI 20–23%). Prevalence was higher in outpatient settings than inpatient settings. Prevalence based on rating scales was higher than studies using diagnostic interviews or clinical record review. Prevalence varied significantly across subspecialist settings for children and adults. No significant time trend was detected between 1981–2023. Pediatric prevalence appears influenced by geographic region but not year of publication or sample size. For adults, larger sample sizes were associated with lower prevalence estimates. Conclusions: ADHD/HD prevalence in clinical populations is 8-9-fold higher than community estimates. With these patients at risk for many adverse outcomes, our findings underscore the critical importance of resource allocation for screening, diagnosing and treatment.
- Open Access
Women with Symptoms Suggestive of ADHD Are More Likely to Report Symptoms of Iron Deficiency and Heavy Menstrual Bleeding
Background/Objectives: Iron deficiency has been suggested as a potential mechanism for attention-deficit hyperactivity disorder (ADHD) development due to involvement in neurotransmitter synthesis and transporter expression. As iron deficiency is particularly common in women of reproductive age, often due to heavy menstrual bleeding (HMB), we aimed to explore the relationship between iron deficiency, HMB and ADHD in women. Methods: We screened women (18–49 years) at university and local sporting events in Western Australia. To screen for ADHD, section A of the Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) and the Adult Concentration Inventory were used to assess cognitive disengagement syndrome (CDS) symptoms. Risk factors for iron deficiency, such as HMB, commonly reported symptoms and a fingerpick haemoglobin concentration (Hb) (Hemocue Hb801) were recorded. Results: Of the 405 completed questionnaires, the mean age was 24.8 ± 10.1 years, the mean Hb was 136.8 ± 12.4 g/L and 6.4% of women were anaemic. Symptoms suggestive of ADHD were reported by 174/405 (43%) women, and 128/405 (32%) women reported HMB. There was a greater prevalence of HMB reported in those experiencing symptoms suggestive of ADHD (39% vs. 26%, p = 0.01). Symptoms of fatigue, dizziness, brain fog, anxiety, heart palpitations, headaches, restless legs and depression were more common in patients with symptoms suggestive of ADHD (p ≤ 0.01) and HMB (p < 0.05). Anaemia status did not influence ADHD status (p = 0.87) nor CDS scores (15.7 ± 7.0 vs. 13.8 ± 6.1, p = 0.17). Conclusions: There is an apparent relationship between those with symptoms reported in ADHD, HMB and iron deficiency. Further exploration is required to determine whether there is a causative relationship.
Open AccessWomen with Symptoms Suggestive of ADHD Are More Likely to Report Symptoms of Iron Deficiency and Heavy Menstrual Bleeding
Background/Objectives: Iron deficiency has been suggested as a potential mechanism for attention-deficit hyperactivity disorder (ADHD) development due to involvement in neurotransmitter synthesis and transporter expression. As iron deficiency is particularly common in women of reproductive age, often due to heavy menstrual bleeding (HMB), we aimed to explore the relationship between iron deficiency, HMB and ADHD in women. Methods: We screened women (18–49 years) at university and local sporting events in Western Australia. To screen for ADHD, section A of the Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) and the Adult Concentration Inventory were used to assess cognitive disengagement syndrome (CDS) symptoms. Risk factors for iron deficiency, such as HMB, commonly reported symptoms and a fingerpick haemoglobin concentration (Hb) (Hemocue Hb801) were recorded. Results: Of the 405 completed questionnaires, the mean age was 24.8 ± 10.1 years, the mean Hb was 136.8 ± 12.4 g/L and 6.4% of women were anaemic. Symptoms suggestive of ADHD were reported by 174/405 (43%) women, and 128/405 (32%) women reported HMB. There was a greater prevalence of HMB reported in those experiencing symptoms suggestive of ADHD (39% vs. 26%, p = 0.01). Symptoms of fatigue, dizziness, brain fog, anxiety, heart palpitations, headaches, restless legs and depression were more common in patients with symptoms suggestive of ADHD (p ≤ 0.01) and HMB (p < 0.05). Anaemia status did not influence ADHD status (p = 0.87) nor CDS scores (15.7 ± 7.0 vs. 13.8 ± 6.1, p = 0.17). Conclusions: There is an apparent relationship between those with symptoms reported in ADHD, HMB and iron deficiency. Further exploration is required to determine whether there is a causative relationship.
- Open Access
Molecular Mechanisms and Therapeutic Potential of Mulberry Fruit Extract in High-Fat Diet-Induced Male Reproductive Dysfunction: A Comprehensive Review
High-fat diet (HFD)-induced obesity represents a significant challenge to male reproductive health, affecting approximately 13% of the global adult population. This comprehensive review synthesizes current evidence regarding mulberry (Morus alba L.) fruit extract’s therapeutic potential for HFD-induced male reproductive dysfunction. Through comprehensive analysis of the peer-reviewed literature from multiple databases (PubMed, Web of Science, Scopus, and Google Scholar; 2005–2024), we evaluated mulberry extract’s effects on testicular morphology, spermatogenesis, sperm parameters, and the underlying molecular mechanisms. Mechanistic studies reveal that standardized mulberry extract mediates protective effects through multiple pathways: enhanced antioxidant enzyme activities (SOD: +45%, Catalase: +38%, GPx: +35%), reduced inflammatory markers (TNF-α: −64%, IL-6: −58%), and modulated NF-κB signaling (−42.3%). These effects are facilitated by mulberry’s rich phytochemical profile, particularly anthocyanins (2.92–5.35 mg/g dry weight) and polyphenols (4.23–6.38 mg/g). The extract demonstrates particular efficacy in preserving seminiferous tubule integrity and maintaining blood-testis barrier function, with treated groups maintaining up to 85% of normal tubular architecture compared to HFD controls. Key molecular mechanisms include AMPK/SIRT1 pathway activation (2.3-fold increase), enhanced mitochondrial function (67% increase in mtDNA copy number), and epigenetic regulation of metabolic pathways. Temporal analysis indicates optimal therapeutic effects after 28 days of treatment, with initial improvements observable within 14 days. While current evidence is promising, limitations include predominant reliance on rodent models and lack of standardized extraction protocols. Future research priorities include well-designed human clinical trials, standardization of preparation methods, and investigation of potential synergistic effects with other therapeutic agents. This comprehensive review indicates that mulberry extract is a promising therapeutic candidate for obesity-related male infertility, warranting further clinical investigation.
Open AccessMolecular Mechanisms and Therapeutic Potential of Mulberry Fruit Extract in High-Fat Diet-Induced Male Reproductive Dysfunction: A Comprehensive Review
High-fat diet (HFD)-induced obesity represents a significant challenge to male reproductive health, affecting approximately 13% of the global adult population. This comprehensive review synthesizes current evidence regarding mulberry (Morus alba L.) fruit extract’s therapeutic potential for HFD-induced male reproductive dysfunction. Through comprehensive analysis of the peer-reviewed literature from multiple databases (PubMed, Web of Science, Scopus, and Google Scholar; 2005–2024), we evaluated mulberry extract’s effects on testicular morphology, spermatogenesis, sperm parameters, and the underlying molecular mechanisms. Mechanistic studies reveal that standardized mulberry extract mediates protective effects through multiple pathways: enhanced antioxidant enzyme activities (SOD: +45%, Catalase: +38%, GPx: +35%), reduced inflammatory markers (TNF-α: −64%, IL-6: −58%), and modulated NF-κB signaling (−42.3%). These effects are facilitated by mulberry’s rich phytochemical profile, particularly anthocyanins (2.92–5.35 mg/g dry weight) and polyphenols (4.23–6.38 mg/g). The extract demonstrates particular efficacy in preserving seminiferous tubule integrity and maintaining blood-testis barrier function, with treated groups maintaining up to 85% of normal tubular architecture compared to HFD controls. Key molecular mechanisms include AMPK/SIRT1 pathway activation (2.3-fold increase), enhanced mitochondrial function (67% increase in mtDNA copy number), and epigenetic regulation of metabolic pathways. Temporal analysis indicates optimal therapeutic effects after 28 days of treatment, with initial improvements observable within 14 days. While current evidence is promising, limitations include predominant reliance on rodent models and lack of standardized extraction protocols. Future research priorities include well-designed human clinical trials, standardization of preparation methods, and investigation of potential synergistic effects with other therapeutic agents. This comprehensive review indicates that mulberry extract is a promising therapeutic candidate for obesity-related male infertility, warranting further clinical investigation.
- Open Access
- 16 December 2024
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 11 (1) , e69628
Correction: An Artificial Therapist (Manage Your Life Online) to Support the Mental Health of Youth: Co-Design and Case Series
[This corrects the article DOI: 10.2196/46849.].
- 16 December 2024
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 11 (1) , e69628
Open AccessCorrection: An Artificial Therapist (Manage Your Life Online) to Support the Mental Health of Youth: Co-Design and Case Series
[This corrects the article DOI: 10.2196/46849.].
- Open Access
- 11 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
A Rule-Based Conversational Agent for Mental Health and Well-Being in Young People: Formative Case Series During the Rise of Generative AI (Preprint)
BACKGROUND There is a shortage of services available to address the growing demand for mental health support in Australia and worldwide. Digital interventions, including conversational agents, can overcome barriers to accessing mental health support. The recent advances in large language models have led to an improvement in the perceived human-like naturalness of chatbot conversations, but there is little research on the experience of chatbots to support mental health. Manage your life online (MYLO) is a rule-based chatbot that was co-designed with young people and uses questions to help users explore their problems. In a case series conducted before the release of ChatGPT (OpenAI), users rated a new smartphone interface for MYLO as acceptable, and there was a large effect size for reduction in problem-related distress. OBJECTIVE This study aimed to evaluate an improved version of MYLO and compare the user experience of MYLO in this case series to the previous version that was completed in November 2022. METHODS We replicated and extended the previous 2-week case-series, conducted from September to November 2022, by testing 4-week usage of MYLO with a larger sample between October and December 2023. We recruited 24 young people living in Western Australia who self-described as having a lived experience of anxiety or depression. Participants had access to and used MYLO over a 4-week period while completing online weekly surveys that included a range of health and psychological questionnaires. After the 4-week testing phase, participants were invited to provide feedback on their experience of using MYLO through an interview or focus group discussion. RESULTS In total, 13 of the 24 participants were retained throughout the study and took part in interviews. On average, participants had around 4 conversations with MYLO. They experienced both benefits and limitations of these conversations. They spoke about their recent experiences with ChatGPT (released in November 2022 after the previous case-series concluded) and other generative artificial intelligence (AI) tools, stating that they had expected MYLO to possess similar functionality, which it did not. Nonetheless, we found moderate to large effect sizes for improvements in problem-related distress (Cohen d=–1.07), anxiety (Cohen d=–0.41), and psychiatric impairment (Cohen d=–0.60) and some evidence of reliable improvement in clinical outcomes. CONCLUSIONS These findings have implications for mental health chatbots in the age of ChatGPT and highlight a need for researchers to engage with new technologies to improve user experience, while maintaining the necessary safety and ethical standards that can be a significant challenge for generative AI.
- 11 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Rule-Based Conversational Agent for Mental Health and Well-Being in Young People: Formative Case Series During the Rise of Generative AI (Preprint)
BACKGROUND There is a shortage of services available to address the growing demand for mental health support in Australia and worldwide. Digital interventions, including conversational agents, can overcome barriers to accessing mental health support. The recent advances in large language models have led to an improvement in the perceived human-like naturalness of chatbot conversations, but there is little research on the experience of chatbots to support mental health. Manage your life online (MYLO) is a rule-based chatbot that was co-designed with young people and uses questions to help users explore their problems. In a case series conducted before the release of ChatGPT (OpenAI), users rated a new smartphone interface for MYLO as acceptable, and there was a large effect size for reduction in problem-related distress. OBJECTIVE This study aimed to evaluate an improved version of MYLO and compare the user experience of MYLO in this case series to the previous version that was completed in November 2022. METHODS We replicated and extended the previous 2-week case-series, conducted from September to November 2022, by testing 4-week usage of MYLO with a larger sample between October and December 2023. We recruited 24 young people living in Western Australia who self-described as having a lived experience of anxiety or depression. Participants had access to and used MYLO over a 4-week period while completing online weekly surveys that included a range of health and psychological questionnaires. After the 4-week testing phase, participants were invited to provide feedback on their experience of using MYLO through an interview or focus group discussion. RESULTS In total, 13 of the 24 participants were retained throughout the study and took part in interviews. On average, participants had around 4 conversations with MYLO. They experienced both benefits and limitations of these conversations. They spoke about their recent experiences with ChatGPT (released in November 2022 after the previous case-series concluded) and other generative artificial intelligence (AI) tools, stating that they had expected MYLO to possess similar functionality, which it did not. Nonetheless, we found moderate to large effect sizes for improvements in problem-related distress (Cohen d=–1.07), anxiety (Cohen d=–0.41), and psychiatric impairment (Cohen d=–0.60) and some evidence of reliable improvement in clinical outcomes. CONCLUSIONS These findings have implications for mental health chatbots in the age of ChatGPT and highlight a need for researchers to engage with new technologies to improve user experience, while maintaining the necessary safety and ethical standards that can be a significant challenge for generative AI.
- Open Access
- 4 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Correction: An Artificial Therapist (Manage Your Life Online) to Support the Mental Health of Youth: Co-Design and Case Series (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 4 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCorrection: An Artificial Therapist (Manage Your Life Online) to Support the Mental Health of Youth: Co-Design and Case Series (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).